Rallybio Reports Third Quarter 2025 Financial Results and Provides Business Updates
– RLYB116 Confirmatory PK/PD Study Data Expected in 4Q 2025 – – Generated $20 Million from Sale of Interest in REV102 – – Cash Runway Extended through... Read more.
Organ Recovery Systems Announces NEJM Publication of Landmark Follow Up 10-Year Kidney Study Comparing LifePort® Hypothermic Machine Perfusion to Static Cold Storage
Follow up substantiates sustained reduced delayed graft function and improved graft survival, especially in expanded-criteria donor (ECD) kidneys Data reinforces... Read more.
CareDx Announces New Precision Kidney Transplant Data and Product Innovations at ASN Kidney Week 2025
CareDx Extends Leadership in Kidney Transplant Molecular Testing with Launch of Unique Tissue-Based Gene Expression Assay – HistoMap Kidney SOUTH SAN FRANCISCO,... Read more.
Brighthouse Financial Cancels Conference Call to Discuss Third Quarter 2025 Results and Provides Select Preliminary Financial Results
CHARLOTTE, N.C.–(BUSINESS WIRE)–Following the issuance of a news release earlier today announcing that Brighthouse Financial, Inc. (“Brighthouse Financial”... Read more.
Aquarian Capital to Acquire Brighthouse Financial
Brighthouse Financial Stockholders to Receive $70.00 per share in $4.1 Billion Transaction; Positions Brighthouse Financial for Strategic Long-Term Growth NEW YORK... Read more.
Tradeweb Reports October 2025 Total Trading Volume of $65.4 Trillion and Average Daily Volume of $2.8 Trillion
October 2025 ADV up 20.7% YoY NEW YORK–(BUSINESS WIRE)–Tradeweb Markets Inc. (Nasdaq: TW), a leading, global operator of electronic marketplaces for... Read more.
Cybin to Announce Second Quarter Financial Results and Provide Business Update on November 13, 2025
– Company to host conference call and webcast at 8:00 a.m. ET on Thursday, November 13, 2025 – TORONTO–(BUSINESS WIRE)–Cybin Inc. (NYSE American:CYBN)... Read more.
NUBURU Strengthens Balance Sheet, Advances Defense-Tech Acquisition Program and Revamps Blue-Laser Business
Executing Transformation Plan spanning Maddox Defense drones, Tekne special-mission vehicles, and Orbit critical-infrastructure software to build a unified defense-tech... Read more.
Silence Therapeutics Reports Third Quarter 2025 Financial Results and Recent Business Highlights
SANRECO Phase 2 study of divesiran in polycythemia vera (PV) fully enrolled; topline results anticipated in 3Q 2026 Strong balance sheet and cash runway into 2028... Read more.
Organon To Report Third Quarter 2025 Results and Host Conference Call on November 10, 2025
JERSEY CITY, N.J.–(BUSINESS WIRE)–Organon (NYSE: OGN), a global healthcare company with a primary focus on women’s health, will release its third quarter... Read more.